| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 30 | 2021 | 116 | 5.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 31 | 2021 | 468 | 3.680 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 9 | 2014 | 29 | 1.930 |
Why?
|
| Multiple Myeloma | 12 | 2020 | 92 | 1.880 |
Why?
|
| Heterocyclic Compounds | 6 | 2016 | 24 | 1.780 |
Why?
|
| Antineoplastic Agents | 14 | 2019 | 1070 | 1.610 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2021 | 245 | 1.360 |
Why?
|
| Cytarabine | 14 | 2021 | 44 | 1.350 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 9 | 2012 | 74 | 1.260 |
Why?
|
| Naphthyridines | 5 | 2018 | 20 | 1.220 |
Why?
|
| Thiazoles | 5 | 2018 | 95 | 1.180 |
Why?
|
| Ankle Injuries | 2 | 2019 | 16 | 1.130 |
Why?
|
| Cyclophosphamide | 14 | 2015 | 129 | 1.060 |
Why?
|
| Joint Instability | 2 | 2019 | 87 | 1.040 |
Why?
|
| Thalidomide | 2 | 2015 | 24 | 0.900 |
Why?
|
| Middle Aged | 71 | 2021 | 21147 | 0.810 |
Why?
|
| Aged | 55 | 2021 | 14862 | 0.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2021 | 44 | 0.780 |
Why?
|
| Bone Marrow Transplantation | 15 | 2003 | 149 | 0.760 |
Why?
|
| Daunorubicin | 6 | 2021 | 20 | 0.760 |
Why?
|
| Hematopoietic Stem Cells | 10 | 2014 | 268 | 0.710 |
Why?
|
| Humans | 127 | 2021 | 68618 | 0.700 |
Why?
|
| Male | 81 | 2021 | 37321 | 0.670 |
Why?
|
| Treatment Outcome | 29 | 2021 | 7029 | 0.670 |
Why?
|
| Lateral Ligament, Ankle | 1 | 2019 | 2 | 0.660 |
Why?
|
| Sprains and Strains | 1 | 2019 | 3 | 0.660 |
Why?
|
| Salvage Therapy | 8 | 2020 | 82 | 0.660 |
Why?
|
| Pyrazines | 7 | 2019 | 46 | 0.660 |
Why?
|
| Female | 79 | 2021 | 38074 | 0.650 |
Why?
|
| Antigens, CD34 | 7 | 2014 | 75 | 0.610 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2020 | 332 | 0.610 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 102 | 0.590 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 47 | 0.580 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 446 | 0.570 |
Why?
|
| Lymphoma | 6 | 2014 | 116 | 0.560 |
Why?
|
| Lymphoma, B-Cell | 5 | 2015 | 40 | 0.550 |
Why?
|
| Recurrence | 13 | 2019 | 948 | 0.540 |
Why?
|
| Adult | 58 | 2020 | 21403 | 0.510 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2019 | 21 | 0.500 |
Why?
|
| Immunologic Factors | 2 | 2015 | 87 | 0.500 |
Why?
|
| Suture Anchors | 1 | 2014 | 9 | 0.480 |
Why?
|
| Ligaments, Articular | 1 | 2014 | 21 | 0.480 |
Why?
|
| Peptic Ulcer Hemorrhage | 5 | 2017 | 26 | 0.480 |
Why?
|
| Aged, 80 and over | 20 | 2020 | 4848 | 0.460 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2013 | 331 | 0.450 |
Why?
|
| Benzylamines | 6 | 2016 | 28 | 0.450 |
Why?
|
| Carbazoles | 2 | 2011 | 46 | 0.440 |
Why?
|
| Leukemia | 9 | 2018 | 117 | 0.440 |
Why?
|
| Antibodies, Monoclonal | 3 | 2015 | 511 | 0.430 |
Why?
|
| Clinical Trials as Topic | 12 | 2013 | 848 | 0.430 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2018 | 63 | 0.410 |
Why?
|
| Mycophenolic Acid | 3 | 2019 | 62 | 0.410 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2014 | 10 | 0.390 |
Why?
|
| Transplantation Conditioning | 4 | 2018 | 34 | 0.380 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 121 | 0.380 |
Why?
|
| Esomeprazole | 5 | 2017 | 9 | 0.380 |
Why?
|
| HLA-DP Antigens | 1 | 2010 | 2 | 0.370 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2010 | 22 | 0.370 |
Why?
|
| Remission Induction | 13 | 2019 | 111 | 0.360 |
Why?
|
| Boronic Acids | 5 | 2014 | 40 | 0.350 |
Why?
|
| Cisplatin | 8 | 2000 | 192 | 0.340 |
Why?
|
| Transplantation, Autologous | 9 | 2021 | 145 | 0.340 |
Why?
|
| Cost Savings | 1 | 2010 | 110 | 0.340 |
Why?
|
| Survival Rate | 13 | 2020 | 1056 | 0.340 |
Why?
|
| Decision Support Techniques | 2 | 2010 | 191 | 0.330 |
Why?
|
| Infusions, Intravenous | 10 | 2021 | 334 | 0.320 |
Why?
|
| Survival Analysis | 11 | 2019 | 714 | 0.320 |
Why?
|
| Young Adult | 11 | 2019 | 5717 | 0.320 |
Why?
|
| Aniline Compounds | 2 | 2019 | 52 | 0.320 |
Why?
|
| Graft vs Host Disease | 3 | 2019 | 163 | 0.310 |
Why?
|
| Blood Component Removal | 3 | 2014 | 19 | 0.310 |
Why?
|
| Prognosis | 11 | 2021 | 2093 | 0.300 |
Why?
|
| Surgical Procedures, Operative | 2 | 2004 | 124 | 0.300 |
Why?
|
| Prospective Studies | 12 | 2020 | 3705 | 0.300 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 3259 | 0.280 |
Why?
|
| Graft Rejection | 1 | 2010 | 458 | 0.280 |
Why?
|
| Lymphoproliferative Disorders | 3 | 2014 | 37 | 0.280 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2011 | 70 | 0.280 |
Why?
|
| Anti-HIV Agents | 3 | 2014 | 135 | 0.280 |
Why?
|
| Drug Administration Schedule | 8 | 2021 | 567 | 0.280 |
Why?
|
| Translocation, Genetic | 3 | 2012 | 74 | 0.260 |
Why?
|
| Adolescent | 18 | 2019 | 8912 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2011 | 129 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 151 | 0.250 |
Why?
|
| Retrospective Studies | 15 | 2018 | 7277 | 0.240 |
Why?
|
| Disease-Free Survival | 10 | 2019 | 349 | 0.240 |
Why?
|
| Pyridines | 2 | 2018 | 261 | 0.240 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2018 | 24 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 90 | 0.240 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2011 | 101 | 0.230 |
Why?
|
| Mutation | 3 | 2019 | 1213 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 125 | 0.220 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 40 | 0.220 |
Why?
|
| Enzyme Inhibitors | 2 | 2018 | 659 | 0.220 |
Why?
|
| Tetrahydrofolates | 3 | 1994 | 28 | 0.210 |
Why?
|
| Leucovorin | 3 | 1994 | 35 | 0.210 |
Why?
|
| Parenteral Nutrition, Total | 3 | 1992 | 22 | 0.210 |
Why?
|
| Bortezomib | 5 | 2014 | 45 | 0.200 |
Why?
|
| Filgrastim | 2 | 2012 | 22 | 0.200 |
Why?
|
| Combined Modality Therapy | 13 | 2014 | 951 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 3 | 2021 | 62 | 0.200 |
Why?
|
| Bone Marrow | 7 | 1990 | 168 | 0.200 |
Why?
|
| Hemostasis, Endoscopic | 3 | 2010 | 17 | 0.200 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2015 | 77 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 3 | 2012 | 504 | 0.190 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2014 | 201 | 0.190 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 742 | 0.190 |
Why?
|
| Polyethylene Glycols | 2 | 2012 | 149 | 0.190 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2011 | 37 | 0.190 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 17 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 137 | 0.190 |
Why?
|
| Algorithms | 3 | 2012 | 1196 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 1745 | 0.180 |
Why?
|
| Hematopoiesis | 8 | 2016 | 108 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 206 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 629 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2011 | 57 | 0.180 |
Why?
|
| Catheterization, Central Venous | 2 | 1992 | 89 | 0.180 |
Why?
|
| Hydrazines | 2 | 2009 | 23 | 0.170 |
Why?
|
| Methotrexate | 2 | 2018 | 91 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2003 | 364 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 4 | 2009 | 561 | 0.170 |
Why?
|
| Phosphoproteins | 3 | 2014 | 202 | 0.170 |
Why?
|
| Tumor Hypoxia | 1 | 2019 | 3 | 0.170 |
Why?
|
| Agranulocytosis | 3 | 1993 | 15 | 0.170 |
Why?
|
| Lysholm Knee Score | 1 | 2019 | 1 | 0.170 |
Why?
|
| Azacitidine | 1 | 2019 | 20 | 0.170 |
Why?
|
| Germinoma | 1 | 1999 | 4 | 0.170 |
Why?
|
| Aminopyridines | 1 | 2019 | 26 | 0.170 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2019 | 35 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 2 | 1992 | 239 | 0.160 |
Why?
|
| Morpholines | 1 | 2019 | 79 | 0.160 |
Why?
|
| Cell Count | 3 | 2018 | 248 | 0.160 |
Why?
|
| Piperidines | 3 | 2020 | 123 | 0.160 |
Why?
|
| Anti-Ulcer Agents | 2 | 2010 | 47 | 0.160 |
Why?
|
| Cyclosporine | 1 | 2019 | 121 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2009 | 141 | 0.160 |
Why?
|
| Administration, Oral | 6 | 2019 | 411 | 0.160 |
Why?
|
| Drug Combinations | 3 | 2019 | 304 | 0.160 |
Why?
|
| Glutathione | 2 | 1991 | 343 | 0.160 |
Why?
|
| Calcineurin Inhibitors | 1 | 2018 | 24 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 18 | 0.160 |
Why?
|
| Ankle Joint | 1 | 2019 | 57 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2019 | 128 | 0.150 |
Why?
|
| Double-Blind Method | 9 | 2017 | 1738 | 0.150 |
Why?
|
| Thrombocytopenia | 3 | 2015 | 122 | 0.150 |
Why?
|
| Glycine | 1 | 2018 | 89 | 0.150 |
Why?
|
| Neoplasm Staging | 5 | 2014 | 800 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 300 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2015 | 39 | 0.150 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 94 | 0.150 |
Why?
|
| Time Factors | 9 | 2015 | 4655 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 127 | 0.140 |
Why?
|
| Transplantation, Homologous | 5 | 2018 | 242 | 0.140 |
Why?
|
| Hemostasis, Surgical | 1 | 2017 | 18 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 1999 | 267 | 0.140 |
Why?
|
| Information Services | 1 | 1997 | 22 | 0.140 |
Why?
|
| Electrocoagulation | 1 | 2017 | 35 | 0.140 |
Why?
|
| Computer Communication Networks | 1 | 1997 | 28 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 132 | 0.140 |
Why?
|
| Dexamethasone | 2 | 2020 | 150 | 0.140 |
Why?
|
| Myeloablative Agonists | 1 | 2016 | 4 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2012 | 144 | 0.140 |
Why?
|
| Epinephrine | 1 | 2017 | 103 | 0.140 |
Why?
|
| Antigen Presentation | 2 | 2015 | 76 | 0.140 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 78 | 0.140 |
Why?
|
| RNA-Binding Proteins | 2 | 2009 | 215 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 107 | 0.140 |
Why?
|
| Neutropenia | 2 | 2015 | 72 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 4 | 2019 | 41 | 0.130 |
Why?
|
| Adenine Nucleotides | 3 | 2012 | 11 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 3 | 2017 | 91 | 0.130 |
Why?
|
| Peptic Ulcer | 2 | 2017 | 37 | 0.130 |
Why?
|
| Breast Neoplasms | 3 | 2000 | 1536 | 0.130 |
Why?
|
| Arabinonucleosides | 2 | 2012 | 2 | 0.130 |
Why?
|
| Phorbols | 4 | 1989 | 8 | 0.130 |
Why?
|
| Colony-Forming Units Assay | 9 | 1992 | 78 | 0.120 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2014 | 19 | 0.120 |
Why?
|
| Tumor Escape | 1 | 2015 | 37 | 0.120 |
Why?
|
| Mastocytosis, Systemic | 1 | 2014 | 3 | 0.120 |
Why?
|
| Animals | 16 | 2014 | 20881 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 536 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2020 | 328 | 0.120 |
Why?
|
| Flavonoids | 2 | 2014 | 109 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 931 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2014 | 329 | 0.120 |
Why?
|
| Adamantane | 1 | 2014 | 40 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 1995 | 330 | 0.120 |
Why?
|
| Erythropoiesis | 3 | 1991 | 24 | 0.120 |
Why?
|
| Patient Selection | 2 | 1999 | 592 | 0.110 |
Why?
|
| Databases, Factual | 1 | 1997 | 622 | 0.110 |
Why?
|
| Cell Survival | 3 | 1991 | 901 | 0.110 |
Why?
|
| Consolidation Chemotherapy | 1 | 2013 | 5 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 649 | 0.110 |
Why?
|
| Furans | 2 | 2011 | 27 | 0.110 |
Why?
|
| Felty Syndrome | 1 | 1993 | 1 | 0.110 |
Why?
|
| Retreatment | 4 | 2017 | 59 | 0.110 |
Why?
|
| Biological Transport | 1 | 2013 | 210 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 626 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2009 | 29 | 0.110 |
Why?
|
| Graft Survival | 3 | 2016 | 465 | 0.110 |
Why?
|
| Aminoglycosides | 1 | 2013 | 54 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2012 | 18 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 5 | 2015 | 852 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2011 | 124 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2013 | 94 | 0.100 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 72 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 1173 | 0.100 |
Why?
|
| Blood Group Incompatibility | 1 | 1991 | 7 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2004 | 64 | 0.100 |
Why?
|
| Creatinine | 1 | 2012 | 243 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 1991 | 15 | 0.100 |
Why?
|
| Drug Costs | 1 | 2012 | 87 | 0.100 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2011 | 6 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1615 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2014 | 2358 | 0.100 |
Why?
|
| Leukemia, B-Cell | 1 | 2011 | 7 | 0.100 |
Why?
|
| Granulocyte-Macrophage Progenitor Cells | 1 | 2011 | 2 | 0.100 |
Why?
|
| Leukemia, Myeloid | 2 | 2010 | 39 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 2 | 2010 | 30 | 0.100 |
Why?
|
| Neoplasms | 6 | 1999 | 1667 | 0.100 |
Why?
|
| Cystitis | 1 | 2010 | 18 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 508 | 0.090 |
Why?
|
| BK Virus | 1 | 2010 | 17 | 0.090 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 17 | 0.090 |
Why?
|
| Ciprofloxacin | 1 | 2010 | 30 | 0.090 |
Why?
|
| Heart Diseases | 2 | 2010 | 276 | 0.090 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 67 | 0.090 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2011 | 63 | 0.090 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 32 | 0.090 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 1991 | 13 | 0.090 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2010 | 6 | 0.090 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2010 | 10 | 0.090 |
Why?
|
| HLA-DP beta-Chains | 1 | 2010 | 4 | 0.090 |
Why?
|
| Secondary Prevention | 4 | 2018 | 291 | 0.090 |
Why?
|
| Mandibular Diseases | 1 | 2010 | 28 | 0.090 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2010 | 22 | 0.090 |
Why?
|
| Stem Cells | 3 | 1990 | 248 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 24 | 0.090 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 11 | 0.090 |
Why?
|
| Blood Cell Count | 1 | 2010 | 35 | 0.090 |
Why?
|
| Quinolones | 1 | 2011 | 60 | 0.090 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 57 | 0.090 |
Why?
|
| Platinum | 1 | 1990 | 17 | 0.090 |
Why?
|
| Sarcoma, Myeloid | 1 | 2009 | 11 | 0.090 |
Why?
|
| Pericardium | 1 | 2010 | 97 | 0.090 |
Why?
|
| Lysophospholipids | 1 | 2011 | 209 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 40 | 0.090 |
Why?
|
| Drug Synergism | 4 | 1991 | 260 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2010 | 514 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2010 | 111 | 0.080 |
Why?
|
| Sphingosine | 1 | 2011 | 315 | 0.080 |
Why?
|
| Liver | 3 | 2019 | 1118 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2009 | 146 | 0.080 |
Why?
|
| Colony-Stimulating Factors | 3 | 1989 | 19 | 0.080 |
Why?
|
| Allografts | 2 | 2019 | 63 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Transplantation, Isogeneic | 2 | 1986 | 19 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 1851 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 41 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1046 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2009 | 97 | 0.080 |
Why?
|
| Polyploidy | 1 | 2008 | 24 | 0.080 |
Why?
|
| Esophageal Stenosis | 1 | 2008 | 36 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1083 | 0.080 |
Why?
|
| Laryngectomy | 1 | 2008 | 30 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 236 | 0.080 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1989 | 138 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 792 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1447 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1664 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 1994 | 778 | 0.080 |
Why?
|
| Adenine | 2 | 2020 | 46 | 0.080 |
Why?
|
| Random Allocation | 4 | 1991 | 442 | 0.080 |
Why?
|
| Injections, Intravenous | 4 | 2009 | 215 | 0.070 |
Why?
|
| Genes, bcl-2 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2014 | 238 | 0.070 |
Why?
|
| Phorbol Esters | 3 | 1981 | 37 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 28 | 0.070 |
Why?
|
| Flow Cytometry | 4 | 2015 | 489 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2010 | 346 | 0.070 |
Why?
|
| Mice | 12 | 2014 | 8474 | 0.070 |
Why?
|
| Sweden | 2 | 2020 | 21 | 0.070 |
Why?
|
| Anemia, Refractory | 1 | 1986 | 1 | 0.070 |
Why?
|
| Fluorouracil | 3 | 1999 | 130 | 0.070 |
Why?
|
| Saudi Arabia | 3 | 2000 | 7 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2014 | 434 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2020 | 178 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2009 | 902 | 0.060 |
Why?
|
| Carbenicillin | 2 | 1982 | 2 | 0.060 |
Why?
|
| Trimethoprim | 2 | 1982 | 8 | 0.060 |
Why?
|
| Sulfamethoxazole | 2 | 1982 | 15 | 0.060 |
Why?
|
| Bone Marrow Cells | 7 | 1990 | 217 | 0.060 |
Why?
|
| Cells, Cultured | 7 | 2009 | 2673 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2007 | 400 | 0.060 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 37 | 0.060 |
Why?
|
| Lymph Node Excision | 1 | 2003 | 91 | 0.060 |
Why?
|
| Oral Surgical Procedures | 1 | 2003 | 15 | 0.050 |
Why?
|
| Child | 9 | 2014 | 6405 | 0.050 |
Why?
|
| Colonic Neoplasms | 2 | 2000 | 299 | 0.050 |
Why?
|
| Microsurgery | 1 | 2003 | 46 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 2007 | 0.050 |
Why?
|
| Rituximab | 2 | 2015 | 61 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2003 | 258 | 0.050 |
Why?
|
| Bacterial Infections | 2 | 1982 | 163 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2000 | 140 | 0.050 |
Why?
|
| Blood Platelets | 2 | 2017 | 284 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 138 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 540 | 0.050 |
Why?
|
| Prednisone | 3 | 2010 | 104 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2021 | 21 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 174 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2017 | 1200 | 0.050 |
Why?
|
| Lung Diseases | 2 | 2009 | 175 | 0.050 |
Why?
|
| Body Height | 2 | 1992 | 67 | 0.050 |
Why?
|
| Nausea | 2 | 2019 | 47 | 0.050 |
Why?
|
| Methionine Sulfoximine | 2 | 1991 | 7 | 0.050 |
Why?
|
| Buthionine Sulfoximine | 2 | 1991 | 10 | 0.050 |
Why?
|
| Life Style | 1 | 2003 | 338 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2000 | 12 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2000 | 36 | 0.040 |
Why?
|
| Kinetics | 3 | 1991 | 1047 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2000 | 63 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2000 | 62 | 0.040 |
Why?
|
| Midazolam | 1 | 2000 | 46 | 0.040 |
Why?
|
| Food Deprivation | 1 | 1979 | 22 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2000 | 61 | 0.040 |
Why?
|
| Vincristine | 2 | 2015 | 44 | 0.040 |
Why?
|
| Emergency Treatment | 1 | 2000 | 52 | 0.040 |
Why?
|
| Misonidazole | 1 | 2019 | 3 | 0.040 |
Why?
|
| Anorexia | 1 | 2019 | 7 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 152 | 0.040 |
Why?
|
| Half-Life | 1 | 2019 | 96 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 191 | 0.040 |
Why?
|
| Risk Factors | 4 | 2012 | 5731 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2000 | 99 | 0.040 |
Why?
|
| Diet | 1 | 2003 | 514 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2000 | 99 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2018 | 120 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 96 | 0.040 |
Why?
|
| Endodermal Sinus Tumor | 1 | 1999 | 1 | 0.040 |
Why?
|
| Dysgerminoma | 1 | 1999 | 9 | 0.040 |
Why?
|
| Monitoring, Physiologic | 2 | 2010 | 219 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 38 | 0.040 |
Why?
|
| Teratoma | 1 | 1999 | 22 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 10 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 54 | 0.040 |
Why?
|
| Fertility | 1 | 1999 | 60 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 86 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.040 |
Why?
|
| Disease Progression | 2 | 2000 | 1038 | 0.040 |
Why?
|
| Regression Analysis | 2 | 1999 | 737 | 0.040 |
Why?
|
| Karyotyping | 2 | 2009 | 74 | 0.040 |
Why?
|
| Liposomes | 1 | 2019 | 107 | 0.040 |
Why?
|
| Piperazines | 2 | 2011 | 206 | 0.040 |
Why?
|
| IgA Deficiency | 1 | 1998 | 3 | 0.040 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 1 | 0.040 |
Why?
|
| Siblings | 1 | 2018 | 34 | 0.040 |
Why?
|
| Platelet Count | 2 | 2016 | 100 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 132 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2015 | 231 | 0.040 |
Why?
|
| Incidence | 3 | 2008 | 1603 | 0.040 |
Why?
|
| Leukemia, Experimental | 2 | 1991 | 14 | 0.040 |
Why?
|
| Parenteral Nutrition | 2 | 1990 | 39 | 0.040 |
Why?
|
| Immunotherapy | 2 | 1993 | 215 | 0.040 |
Why?
|
| Cell Line | 3 | 1991 | 1752 | 0.040 |
Why?
|
| Etoposide | 2 | 2015 | 64 | 0.040 |
Why?
|
| Age Factors | 3 | 2012 | 1864 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1997 | 24 | 0.040 |
Why?
|
| Computer Systems | 1 | 1997 | 42 | 0.040 |
Why?
|
| Computer Security | 1 | 1997 | 19 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 1420 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 89 | 0.040 |
Why?
|
| Spleen | 3 | 1990 | 301 | 0.040 |
Why?
|
| Systems Analysis | 1 | 1997 | 33 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1140 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2017 | 44 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 48 | 0.030 |
Why?
|
| South Carolina | 2 | 2008 | 2752 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2018 | 195 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2004 | 2800 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Quality of Life | 1 | 2004 | 1515 | 0.030 |
Why?
|
| Stomatitis | 1 | 1995 | 8 | 0.030 |
Why?
|
| Models, Statistical | 1 | 1999 | 448 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 204 | 0.030 |
Why?
|
| Naphthalimides | 1 | 2015 | 5 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2015 | 5 | 0.030 |
Why?
|
| Prednisolone | 1 | 2015 | 23 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 16 | 0.030 |
Why?
|
| Splicing Factor U2AF | 1 | 2014 | 1 | 0.030 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 1 | 0.030 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2014 | 7 | 0.030 |
Why?
|
| RNA Splicing Factors | 1 | 2014 | 4 | 0.030 |
Why?
|
| Research Design | 1 | 1979 | 729 | 0.030 |
Why?
|
| Antigens, Surface | 2 | 1986 | 71 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2014 | 13 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 19 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 59 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 24 | 0.030 |
Why?
|
| Pilot Projects | 2 | 1997 | 1342 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 65 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 159 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 76 | 0.030 |
Why?
|
| Autografts | 1 | 2014 | 22 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 69 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1851 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1995 | 131 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 107 | 0.030 |
Why?
|
| Bone Marrow Purging | 1 | 1993 | 2 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 284 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 233 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 307 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2014 | 183 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 304 | 0.030 |
Why?
|
| Folic Acid | 1 | 1994 | 123 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 271 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 506 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 447 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 230 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1995 | 307 | 0.030 |
Why?
|
| Glycoproteins | 2 | 1986 | 238 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Arthritis | 1 | 1993 | 53 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 16 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2012 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 411 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 306 | 0.030 |
Why?
|
| Reference Values | 2 | 1994 | 579 | 0.030 |
Why?
|
| Hemagglutinins | 1 | 1991 | 3 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 30 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 195 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1991 | 110 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 26 | 0.020 |
Why?
|
| Farnesyltranstransferase | 1 | 2011 | 5 | 0.020 |
Why?
|
| Chymotrypsin | 1 | 2011 | 11 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 76 | 0.020 |
Why?
|
| Blood Transfusion | 2 | 1998 | 205 | 0.020 |
Why?
|
| Nucleoside Transport Proteins | 1 | 2010 | 4 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1991 | 111 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 20 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 45 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1992 | 230 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2011 | 85 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2011 | 169 | 0.020 |
Why?
|
| Proteasome Inhibitors | 1 | 2011 | 29 | 0.020 |
Why?
|
| Azathioprine | 1 | 2010 | 16 | 0.020 |
Why?
|
| Virus Activation | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 27 | 0.020 |
Why?
|
| Gingival Diseases | 1 | 2010 | 22 | 0.020 |
Why?
|
| United States | 3 | 2010 | 7367 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 216 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 76 | 0.020 |
Why?
|
| Cell Division | 3 | 1980 | 541 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 33 | 0.020 |
Why?
|
| Oral Ulcer | 1 | 2010 | 22 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 36 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2010 | 23 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1990 | 57 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 55 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 56 | 0.020 |
Why?
|
| Child, Preschool | 5 | 2007 | 3187 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2010 | 54 | 0.020 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1990 | 11 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1692 | 0.020 |
Why?
|
| Leukemia L1210 | 1 | 1990 | 14 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 164 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2009 | 6 | 0.020 |
Why?
|
| Spain | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 156 | 0.020 |
Why?
|
| Antimetabolites | 1 | 1990 | 17 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 13 | 0.020 |
Why?
|
| Aftercare | 1 | 2010 | 114 | 0.020 |
Why?
|
| Equipment Failure | 1 | 1990 | 112 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2009 | 24 | 0.020 |
Why?
|
| Models, Economic | 1 | 2010 | 69 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1990 | 73 | 0.020 |
Why?
|
| Europe | 1 | 2009 | 196 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 63 | 0.020 |
Why?
|
| Monocytes | 2 | 2000 | 210 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 77 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2009 | 117 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 160 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1989 | 11 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 289 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1989 | 37 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 166 | 0.020 |
Why?
|
| Interleukin-3 | 1 | 1989 | 63 | 0.020 |
Why?
|
| Growth Substances | 1 | 1989 | 77 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2007 | 765 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2009 | 175 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 432 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 107 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2008 | 24 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1989 | 96 | 0.020 |
Why?
|
| Actins | 1 | 2009 | 249 | 0.020 |
Why?
|
| Osteoradionecrosis | 1 | 2008 | 7 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1990 | 397 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 710 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2009 | 193 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1641 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1990 | 601 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 2 | 1987 | 17 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 567 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 201 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 1987 | 26 | 0.020 |
Why?
|
| RNA Stability | 1 | 2007 | 55 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1174 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 155 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2008 | 171 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2008 | 226 | 0.020 |
Why?
|
| Antilymphocyte Serum | 2 | 1983 | 52 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1986 | 31 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2007 | 305 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1986 | 86 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 1987 | 157 | 0.020 |
Why?
|
| Deglutition | 1 | 2008 | 221 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 1986 | 114 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 256 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 1426 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1984 | 24 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 780 | 0.010 |
Why?
|
| Gene Expression | 1 | 2007 | 770 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1986 | 370 | 0.010 |
Why?
|
| Body Composition | 1 | 1984 | 119 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1967 | 301 | 0.010 |
Why?
|
| Thoracic Duct | 1 | 1983 | 6 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 1983 | 10 | 0.010 |
Why?
|
| Granulocytes | 1 | 1983 | 22 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1985 | 222 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 1619 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1986 | 617 | 0.010 |
Why?
|
| Psychometrics | 1 | 2004 | 514 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 2689 | 0.010 |
Why?
|
| Health Status | 1 | 2004 | 429 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1988 | 597 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 2891 | 0.010 |
Why?
|
| Ouabain | 1 | 1980 | 32 | 0.010 |
Why?
|
| Delaware | 1 | 2000 | 4 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1999 | 67 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1988 | 839 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1999 | 44 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 228 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1979 | 181 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1980 | 420 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 2077 | 0.010 |
Why?
|
| Acute Disease | 3 | 1986 | 658 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1980 | 248 | 0.010 |
Why?
|
| Vitamins | 1 | 1979 | 134 | 0.010 |
Why?
|
| Informed Consent | 1 | 1979 | 127 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1998 | 43 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1998 | 79 | 0.010 |
Why?
|
| Glucose | 1 | 1979 | 307 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1998 | 306 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1999 | 880 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 47 | 0.010 |
Why?
|
| Macrophages | 1 | 1980 | 647 | 0.010 |
Why?
|
| Body Water | 2 | 1987 | 35 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2000 | 1034 | 0.010 |
Why?
|
| Extracellular Space | 2 | 1987 | 121 | 0.010 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 1992 | 7 | 0.010 |
Why?
|
| Complement System Proteins | 2 | 1983 | 135 | 0.010 |
Why?
|
| Vomiting | 1 | 1990 | 56 | 0.010 |
Why?
|
| Splenic Neoplasms | 1 | 1988 | 5 | 0.000 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 27 | 0.000 |
Why?
|
| Prothrombin Time | 1 | 1967 | 24 | 0.000 |
Why?
|
| Fibrinolysis | 1 | 1967 | 55 | 0.000 |
Why?
|
| Antigens, Neoplasm | 1 | 1988 | 132 | 0.000 |
Why?
|
| Photolysis | 1 | 1987 | 16 | 0.000 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1986 | 5 | 0.000 |
Why?
|
| Diuretics | 1 | 1987 | 97 | 0.000 |
Why?
|
| Busulfan | 1 | 1986 | 13 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1986 | 94 | 0.000 |
Why?
|
| Whole-Body Irradiation | 1 | 1986 | 52 | 0.000 |
Why?
|
| Leukocytes | 1 | 1986 | 99 | 0.000 |
Why?
|
| Fetal Blood | 1 | 1986 | 131 | 0.000 |
Why?
|
| Cell Separation | 1 | 1986 | 132 | 0.000 |
Why?
|
| Leukopenia | 1 | 1985 | 23 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 2 | 1983 | 2791 | 0.000 |
Why?
|
| Nitrogen | 1 | 1985 | 57 | 0.000 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1984 | 14 | 0.000 |
Why?
|
| Bromine | 1 | 1984 | 8 | 0.000 |
Why?
|
| Nutritional Requirements | 1 | 1985 | 57 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1984 | 40 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1985 | 238 | 0.000 |
Why?
|
| Liver Neoplasms | 1 | 1988 | 334 | 0.000 |
Why?
|
| Androgens | 1 | 1983 | 41 | 0.000 |
Why?
|
| Immune Adherence Reaction | 1 | 1983 | 2 | 0.000 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1983 | 66 | 0.000 |
Why?
|
| Antibody Specificity | 1 | 1983 | 98 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1984 | 221 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1983 | 165 | 0.000 |
Why?
|
| Freezing | 1 | 1983 | 29 | 0.000 |
Why?
|
| Tissue Preservation | 1 | 1983 | 44 | 0.000 |
Why?
|
| Body Weight | 1 | 1985 | 554 | 0.000 |
Why?
|
| Immunoglobulin M | 1 | 1983 | 172 | 0.000 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1982 | 22 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1983 | 532 | 0.000 |
Why?
|
| Gentamicins | 1 | 1982 | 68 | 0.000 |
Why?
|
| Cocarcinogenesis | 1 | 1981 | 4 | 0.000 |
Why?
|
| Models, Biological | 1 | 1985 | 981 | 0.000 |
Why?
|
| Clone Cells | 1 | 1980 | 67 | 0.000 |
Why?
|
| Isoantigens | 1 | 1980 | 26 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1980 | 107 | 0.000 |
Why?
|
| Epitopes | 1 | 1980 | 146 | 0.000 |
Why?
|
| Alcoholism | 1 | 1967 | 1109 | 0.000 |
Why?
|